Harnessing the Evidence: Implementing NCPA and NABP’s PhARM-OUD Guidelines to Improve Access To Buprenorphine in Your Pharmacy
Sponsored by the Foundation for Opioid Response Efforts
Nov. 14, 2 p.m. ET
Buprenorphine is the only agonist medication for opioid use disorder that can be dispensed in all community in the United States. With the passage of the Mainstreaming Addiction Treatment Act in late 2022, any DEA-licensed prescriber can now prescribe buprenorphine for the treatment of OUD. This landmark legislation promises to extend access to buprenorphine; still, only around half of all pharmacies in the United States stock buprenorphine.
In this session, Tyler Varisco, PharmD, PhD, will review the evidence supporting the safe and effective use of buprenorphine before reviewing the creation of the PhARM-OUD Guideline and implementing its recommendations in practice.
Shifting Your Asthma Rescue Therapy Approach in 2024
Sponsored by AstraZeneca
Nov. 19, 2 p.m. ET
How do you approach rescue therapy for your patients with asthma? Join us as we examine the role of variable inflammation in the occurrence of asthma exacerbations and the consequent burden of systemic corticosteroid exposures. See recent recommendations from Global Initiative for Asthma and National Asthma Education and Prevention Program and hear about data on a rescue therapy option that may broaden your perspective.
CE Webinar Archive
Miss a prior CE Webinar? Visit ncpa.org/learn to find our entire catalog of on Demand CE course offerings